%0 Journal Article
%A Luke, Jason J
%A Ascierto, Paolo A
%A Khattak, Muhammad A
%A Rutkowski, Piotr
%A Del Vecchio, Michele
%A Spagnolo, Francesco
%A Mackiewicz, Jacek
%A Merino, Luis de la Cruz
%A Chiarion-Sileni, Vanna
%A Kirkwood, John M
%A Robert, Caroline
%A Schadendorf, Dirk
%A de Galitiis, Federica
%A Carlino, Matteo S
%A Dummer, Reinhard
%A Mohr, Peter
%A Odeleye-Ajakaye, Amos
%A Fukunaga-Kalabis, Mizuho
%A Krepler, Clemens
%A Eggermont, Alexander M M
%A Long, Georgina V
%T Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
%J European journal of cancer
%V 220
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-00757
%P 115381
%D 2025
%X Adjuvant pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB/IIC melanoma in KEYNOTE-716. Results of a post hoc 4-year analysis are reported, including progression/recurrence-free survival 2 (PRFS2).Patients were randomly assigned 1:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks (part 1). RFS was the primary end point; DMFS was secondary. Patients with recurrence following placebo or 17 cycles of pembrolizumab could cross over to or be rechallenged with pembrolizumab (part 2).Median follow-up (n = 976) was 52.8 months (range, 39.4-64.8). RFS (HR, 0.62 [95 
%K Adjuvant therapy (Other)
%K Immune checkpoint inhibitors (Other)
%K Melanoma (Other)
%K Pembrolizumab (Other)
%K Programmed cell death protein 1 (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40198940
%R 10.1016/j.ejca.2025.115381
%U https://inrepo02.dkfz.de/record/300307